BCL2L1 and prostate cancer: Mechanistically, exosomal miR-145 from adipose-derived stromal cells, or ASCs, may also serve as a therapeutic target for prostate cancer, as it has been shown to reduce Bcl-xL activity and promote prostate cancer cell apoptosis via the caspase-3/7 pathway [85].